Shionogi to Acquire IntraBio for $2 Billion

Shionogi has agreed to acquire Austin, Texas-based drugmaker Intra Bio for $2 billion. The Japanese drugmaker announced Monday that Intra Bio’s expertise will strengthen its rare disease pipeline. Through the transaction, Shionogi will obtain global rights, including intellectual property and commercialization rights, for Aqneursa, which is approved in the U.S. and the European Union for treating neurological manifestations of Niemann-Pick disease type C.

The Japanese company will acquire shares of Intra Bio from existing shareholders, including individuals, trusts, and corporate entities. The acquisition is scheduled to be completed between November and December, according to Shionogi.

信越已同意以20亿美元收购位于美国德克萨斯州奥斯汀市的制药公司Intra Bio。日本这家制药公司周一宣布，Intra Bio的专业知识将增强其罕见病药物研发管线。通过此次交易，信越将获得Aqneursa的全球权利，包括知识产权和商业化权利，该药物已在美国和欧盟获准用于治疗尼曼-皮克C型疾病的神经系统表现。这家日本公司将从现有股东（包括个人、信托和企业实体）处收购Intra Bio的股份。据信越称，此次收购计划于11月至12月期间完成。